PENTA15: Plasma Pharmacokinetic Study of Once Versus Twice Daily Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV-1 Infection Aged 3 Months to <36 Months

Trial Profile

PENTA15: Plasma Pharmacokinetic Study of Once Versus Twice Daily Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV-1 Infection Aged 3 Months to <36 Months

Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2014

At a glance

  • Drugs Abacavir (Primary) ; Lamivudine
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Acronyms PENTA15
  • Most Recent Events

    • 20 Nov 2013 New source identified and integrated: ClinicalTrials.gov record.
    • 07 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top